SLC18A2 and Huntington disease: Together, these data suggest that following unilateral HD-LRRK2G2019S injection into the SN, LRRK2G2019S increased pTauSer395/Ser404 levels, but did not induce changes in nigrostriatal terminal density or glucose metabolism in the striatum, or the number of VMAT2+ cells in the SN.